ARTICLE | Product Development

AstraZeneca, GSK identify early treatment opportunities with big impact for cancer patients

BioCentury’s ASCO wrap includes analysis of Tagrisso, Imfinzi and Jemperli readouts

June 7, 2024 10:55 PM UTC

The 2024 ASCO conference has proven just how transformational targeted and immunotherapies can be when they’re applied early in disease. As cancer treatments become more effective and less toxic, moving them up in the treatment paradigm — into entirely new settings for systemic therapies — is putting cures within reach for more patients. 

Several of the biggest readouts presented at this year’s American Society of Clinical Oncology (ASCO) conference highlight new opportunities for systemic therapies that didn’t exist before. These are places where patient outcomes can be dramatically improved by preventing disease recurrence or avoiding life-altering surgeries, and where untapped commercial opportunity exists. ...